Optimal first-line and second-line treatments for metastatic renal cell carcinoma: current evidence

References

• MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaJ Clin Oncol200927223584359019487381
   PubMed Web of Science ®Google Scholar
• MotzerRJHutsonTETomczakPSunitinib versus interferon alfa in metastatic renal-cell carcinomaN Engl J Med2007356211512417215529
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• RiniBIEscudierBTomczakPComparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trialLancet201137898071931193922056247
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSPhase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factorsCancer2010116184256426520549832
   PubMed Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trialLancet2008372963744945618653228
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network, Kidney Cancer version 22014 Available from: http://www.jnccn.org/content/12/2/175.fullAccessed July 1, 2014
   Google Scholar
• EscudierBEisenTPortaCRenal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201223Suppl 7vii65vii71
   Web of Science ®Google Scholar
• EscudierBBellmuntJNegrierSPhase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survivalJ Clin Oncol201028132144215020368553
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEPhase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206J Clin Oncol201028132137214320368558
   PubMed Web of Science ®Google Scholar
• MotzerRJMcCannLDeenKPazopanib versus sunitinib in renal cancerN Engl J Med201336920197024224635
   PubMedGoogle Scholar
• PiaggioGElbourneDRPocockSJReporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statementJAMA2012308242594260423268518
   PubMed Web of Science ®Google Scholar
• WolterPBeuselinckBPansSFlare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitorsActa Oncol200948462162419107622
   PubMed Web of Science ®Google Scholar
• EscudierBPortaCBonoPRandomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES studyJ Clin Oncol4312014 [Epub ahead of print.]
   Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEBevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206J Clin Oncol200826335422542818936475
   PubMed Web of Science ®Google Scholar
• MotzerRJBacikJMurphyBAInterferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinomaJ Clin Oncol200220128929611773181
   PubMed Web of Science ®Google Scholar
• HengDYXieWReganMMPrognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter studyJ Clin Oncol200927345794579919826129
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med2007356222271228117538086
   PubMed Web of Science ®Google Scholar
• DutcherJPSouzaPMcDermottDEffect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologiesMed Oncol200926220220919229667
   PubMed Web of Science ®Google Scholar
• TamaskarIGarciaJAElsonPAntitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapyJ Urol20081791818817997441
   PubMed Web of Science ®Google Scholar
• SablinMPNegrierSRavaudASequential sorafenib and sunitinib for renal cell carcinomaJ Urol20091821293419447417
   PubMed Web of Science ®Google Scholar
• DudekAZZolnierekJDhamASequential therapy with sorafenib and sunitinib in renal cell carcinomaCancer20091151616719051290
   PubMed Web of Science ®Google Scholar
• PortaCProcopioGCarteniGSequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient casesBJU Int20111088 Pt 2E250E25721599821
   PubMed Web of Science ®Google Scholar
• HutsonTEEscudierBEstebanERandomized Phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinomaJ Clin Oncol201432876076724297950
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib in advanced clear-cell renal-cell carcinomaN Engl J Med2007356212513417215530
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trialJ Clin Oncol200927203312331819451442
   PubMed Web of Science ®Google Scholar
• ZustovichFLombardiGNicolettoOSecond-line therapy for refractory renal-cell carcinomaCrit Rev Oncol Hematol201283111212221944739
   PubMed Web of Science ®Google Scholar